New (non-immunotherapeutic) treatment-strategies for AML/MDS-patients are under development. Dendritic cells (DCs) and ‘leukemia-derived DC’ (DC_leu) connect the innate and the adaptive immunesystem and (re-)activate it, in their capacity as professional antigen-presenting cells (APCs). They can be generated ex vivo from peripheral blood mononuclear cells (PBMNCs) or whole blood (WB), containing the –physiological-cellular/soluble microenvironment of individual patients using various DC/DC_leu-generating methods or (for WB) minimalized ‘Kits’, containing granulocyte-macrophage-colony-stimulating-factor (GM-CSF) and a second response-modifier. Proof for DC/DC_leu-mediated activation of the immune-system after T-cell-enriched mixed lymphocyte culture (MLC) is done by flowcytometry, demonstrating increased fractions of certain activated, leukemia-specific or antileukemic cell-subsets of the innate and the adaptive immune-system.

Generation of DC/DC_leu is possible independent of patients' age, MHC-, mutation- or transplantation-status. In vivo-treatment of AML-/MDS-patients with blast-modulating, DC/DC_leu- inducing ‘Kits’ could contribute to create migratory DCs, as well as antileukemically reactivated and memory-mediating immune-cells, which patrol tissue and blood and could contribute to stabilizing disease or remissions.

针对AML / MDS患者的新（非免疫治疗）治疗策略正在开发中。树突状细胞（DC）和“白血病衍生的DC”（DC _leu）连接先天性和适应性免疫系统，并以其作为专业抗原呈递细胞（APC）的能力（重新）激活它。它们可以离体产生自外周血单核细胞（PBMNC）或全血（WB），其中包含使用各种DC / DC _leu产生方法或（对于WB）最小化的'Kits'试剂盒，每个患者的–生理细胞/可溶性微环境含有粒细胞-巨噬细胞集落刺激因子（GM-CSF）和第二种反应调节剂。DC / DC _leu的证明T细胞富集的混合淋巴细胞培养（MLC）后，通过流式细胞术完成了免疫介导的免疫系统激活，表明先天性和适应性免疫系统的某些活化，白血病特异性或抗白血病细胞亚群的比例增加。

DC / DC _leu的产生可能与患者的年龄，MHC，突变或移植状态无关。用爆炸调节DC / DC _leu诱导的“试剂盒”对AML / MDS患者进行体内治疗，可能有助于产生迁移性DC，以及抗白血病活化和记忆介导的免疫细胞，巡逻组织和血液并可能有助于稳定疾病或缓解症状。